Introduction
In addition to traditional morphological and functional strategies, including physiological and pharmacological tools, innovative approaches are necessary to investigate molecular, cellular and neuroendocrine correlates of behavior. Neuroendocrine as well as behavioral regulation, particularly in mammals, is a priori complex at multiple levels, justifying the use of various complementary techniques. Among them, antisense targeting has proven to be a valuable tool for studying peptide and protein functions in vivo even in the intact brain, which provides a particular challenge but also a promise for those interested in antisense targeting. On the one hand, both the blood-brain barrier and the heterogeneity of the brain make efficient and selective antisense targeting difficult to achieve. But on the other hand, the brain as a whole or even an individual neuron with its capability of producing hundreds of biologically active neuropeptides and receptor and other proteins may be particularly amenable to the use of antisense approaches, especially when few specific traditional pharmacological agents exist.
In neuroendocrinology those antisense studies dominate that focus on neuropeptides and receptors of neuropeptides or steroids. The number of such studies using antisense targeting in vivo peaked in 1994 and 1995, with about 20 papers published in each of those years (in 1993, about 5 papers were published and in 1996, about 15). This development, which is similar for corresponding behavioral studies (including those on autonomic effects; from 1993 to 1996 about 10, 30, 25 and 20 papers respectively were published), appears to be normal for a new and promising technique and reflects the initial enthusiasm just as much as its subsequent more expert use and the realization of considerable pitfalls. The antisense papers published so far in behavioral neuroscience (including autonomic effects) have described effects on (order according to the number of published papers) antinociception, motor regulation, feeding and drinking, reproductive behaviors, anxiety, learning and memory, and on cardiovascular and temperature regulation.
By weighing the advantages and disadvantages of antisense targeting, this short review is aimed at stimulating and qualifying the reader to use antisense oligodeoxynucleotides (ODN) in vivo to study mechanisms underlying the regulation of neuroendocrine systems and behavior. Although a detailed methodological discussion is beyond the scope of this article and the methodology has already been reviewed by others (1) (2) (3) (4) (5) (6) (7) (8) , some of the problems we are facing in the actual application of antisense ODN to the brain of conscious rats are briefly discussed in terms of administration, chemical modification, proper controls, mechanisms of antisense action and specificity in vivo. Furthermore, this review will highlight the literature on antisense effects on neuroendocrine systems and behavioral performance, with emphasis on those studies that include both neuroendocrine and behavioral parameters as well as our own attempts in this direction.
Administration and cellular uptake of ODN
The brain is efficiently protected by the blood-brain barrier and the consequent need for central administration of ODN with minimal stress to freely moving animals turns out to be a considerable obstacle. An intracerebroventricular approach is often used, which is easy to perform even in freely moving rats and, more importantly, results in a virtually even distribution of the injected substances throughout at least circumventricular areas. This may be advantageous if, for instance, brain loci situated bilaterally in the vicinity of the ventricular system are to be targeted. In order to avoid processes that minimize antisense actions such as marked dilution following administration and enzymatic degradation, and to increase local specificity, we usually infuse ODN directly into the brain area of interest, either acutely or continuously via sustained delivery devices such as osmotic minipumps. As the turnover of the target protein is a key factor in the successful reduction of expression, a single antisense administration often does not produce any significant physiological modification when the target protein has a long half-life or when large neuronal stores of the targeted neuropeptide are available. It is thus important to select empirically the appropriate mode of administration and the appropriate time intervals to reveal antisense-induced alterations at different levels.
The uptake mechanisms into cells for antisense probes are still poorly understood and have generally been evaluated in carcinoma or myeloid cells and in mixed neural cultures. These attempts have still to be proved successful in vivo but, especially in the brain, the successful transformation of in vitro data to in vivo conditions is rather rare (9, 10) . Thus, one of the major goals is to delineate the biodistribution and pharmacokinetic behavior of antisense ODN and to develop effective means for delivering ODN to the cytoplasm of neurons in vivo.
Generally, charged ODN are unlikely to diffuse passively through neuronal membranes and to gain access to mRNA in intact cells in vivo. This is a major issue. It appears that ODN internalization in neurons depends predominantly on endocytosis, including fluidphase endocytosis (pinocytosis). Irrespective of the relative contribution of different processes of internalization, the net result is identical as the ODN will enter the endosomal compartment, i.e. the bulk of the internalized ODN will be trapped in intracellular vesicles. These early endosomes are then transformed into late endosomes and finally into lysosomes. The rate of loss of ODN from the endosomal/lysosomal compartment into the cytoplasm is probably low. If the ODN remain within the vesicle they are likely to be sequestered and degraded in lysosomes, with little or no intact ODN entering the cytosol compartment. Since the targets for antisense ODN reside exclusively in the latter, a major challenge is how to transport ODN through the vesicle membrane into the cytosol in a manner suitable for efficient mRNA binding.
Over the past several years many approaches have been tried to improve the efficacy of antisense treatment by destabilizing the endosomal membrane. One of these (11) is based on the fact that the pH within the endosomes and lysosomes is only 4.5, whereas the cytosolic pH is 7. A peptide engine may undergo reversible pH-mediated transitions between a watersoluble form and a lipid-soluble form. On acidification, the engine undergoes a transition to its lipid-soluble a-helical form wherein its acid moieties are masked from the environment via H-bonded acid dimers, and the amide moieties of the backbone are shielded from the environment via H-bonding within the a-helix. This approach might provide an alternative wherein the engine imparts good aqueous solubility while in the extracellular compartment, at the same time providing effective transport across the endosomal membrane into the cytosol. The practicability of this protection of ODN from lysosomal degradation by virtue of transport out of endosomes prior to conversion of the late endosome to a lysosome will need to be demonstrated in the brain in vivo.
Chemical modification of ODN
Once within the cells, ODN may be subject to degradation. This problem of instability can be overcome by using chemical modifications including the phosphorothioate modification (where one of the non-bridging oxygens in the phosphodiester backbone is replaced with a sulfur), which in addition to increasing the resistance seems to improve penetration. Concerns about nonspecific protein binding and toxicity of phosphorothioate modifications have led to the development of an endcapped version and of 'chimeric' molecules. Whereas in the former the replacement of oxygen by sulfur is restricted to two positions at the 3 0 and 5 0 end to inhibit primarily exonucleases, the latter are represented by sequences containing a minimal core of RNase H-recruiting phosphorothioate DNA and flanking sequences that are modified to confer affinity, nuclease stability and specificity. When these modifications were used, no generalized toxicity was found (12) (13) (14) . Although, in general, phosphorothioates at present represent the most stable backbones, work with more novel backbones that are currently under development (7) might overcome stability problems while avoiding the (weak) toxicity of phosphorothioates.
In a survey of many in vitro studies, Crooke (15) found that toxic concentrations of ODN range from 0.5-50 mmol/l depending on the particular ODN and the targeted cell type. In general, it is difficult to assess the effectiveness of each ODN relative to its propensity to produce toxicity. The latter is difficult to determine as corresponding assessments have used cell death as the final endpoint. This obviously represents the extreme of toxic actions that may be present in more subtle forms at lower doses. This underlines the need to use scrambled-sequence ODN as controls although even in this case an intracellular distribution different from that of antisense ODN might mask toxic antisense effects. It is conceivable, for instance, that an accumulation of antisense molecules in an intracellular compartment of action induces weak toxic effects, whereas a more or less equal intracellular distribution of scrambled-sequence molecules does not. Furthermore, one has to keep in mind that neuronal subpopulations may be specifically targeted by particular ODN sequences by hitherto unknown mechanisms. This apparent cellular selectivity might make it extremely difficult to recognize toxic effects.
Controls in antisense studies
Proper controls are a major issue in antisense targeting (4); in testing for toxic and antisense-specific effects the minimum requirement is to have vehicle and scrambled-sequence ODN. There are some problems related to the use of sense ODN as controls because sense probes seem to have sequence-specific actions on target cells. Although these effects are described as being subtle to moderate (12, 16, 17) their potency may be equal to that of antisense ODN (18) . As already mentioned, other chemical modifications of the antisense ODN may be useful controls. Molecular, cellular or behavioral responses similar to those with the phosphorothioated version would confirm an antisense mechanism of action rather than toxic effects. A more biological control would be an antisense ODN directed towards another mRNA, which, although related to the mRNA of interest, should not be involved in the regulation of the respective neuroendocrine or behavioral parameters. Furthermore, biological controls would also include the measurement of, for instance, neuropeptides or receptor proteins related to those of interest but not targeted by the antisense ODN.
As far as antisense-induced neuroendocrine and behavioral alterations are concerned, a kind of additional 'internal' control would be to detect molecular and cellular correlates. Such a combined approach might make findings of neuroendocrine and behavioral alterations more convincing, revealing expected changes in underlying pathways and mechanisms. It is, however, hampered by the fact that a linear relationship between, for instance, intracerebral neuropeptide release, changes in receptor characteristics and behavioral alterations are the exception rather than the rule. It is conceivable, in this context, that not all receptors of a given brain area are equally involved in a certain function, i.e. even marked changes in receptor density would not necessarily result in an altered behavior, but a local fluctuation not detectable by receptor autoradiography can have significant behavioral consequences. Interestingly, local mRNA levels following antisense treatment were found to be unchanged, decreased or even elevated (12, 19, 20) indicating that taken by themselves such alterations do not allow any conclusions to be drawn as to the antisense-induced mechanisms of action. Taken together with neuropeptide/receptor protein changes in the same brain area during the same time interval, however, they may provide valuable information.
Another (and often ignored) obstacle to combined molecular, cellular and behavioral approaches is the need to verify the locus of administration, particularly if very small brain areas such as hypothalamic nuclei were chosen. At least in this case, the highest priority should be given to histology rather than to approaches such as autoradiography, radioimmunoassay and in situ hybridization.
Mechanisms of action and specificity
In theory, any peptide or receptor protein, if a portion of its transcript sequence is known, can be specifically targeted for downregulation, even if other very similar sequences are expressed. The complementary base binding of antisense targeting offers a degree of specificity that cannot be achieved through conventional pharmacological strategies. However, hardly any other in vivo approach requires such extensive controls in terms of specificity, toxicity and mechanisms of action.
Treatment with short, single-stranded antisense ODN is believed to reduce peptide or protein expression by several mechanisms, including inhibition of RNA translation and formation of RNA/DNA hybrids recognized and degraded by RNase H. Translational arrest can result from steric blockade of enzymes that would normally interact with the single-stranded mRNA. This could lead to an inhibition of precursor mRNA processing, transport from the nucleus and/or mRNA translation. RNase H recognizes DNA/RNA heteroduplexes in the cytoplasm and degrades the RNA segment, in this way destabilizing and degrading the entire RNA molecule; however, as commonly thought, this enzyme is unlikely to play a major role in specific brain areas. Inhibition of gene expression at the transcriptional level can also be achieved with triplex-forming ODN (10) provided the target sequence is accessible within the chromatin structure of cell nuclei.
In addition to these antisense mechanisms of action, which are likely to result in a detectable decrease in the peptide/protein in the brain area of interest, increasing evidence indicates the possibility of non-antisense mechanisms of action, which are sequence-specific and not primarily related to a decreased content and availability of the gene product. Recently, Neumann et al. succeeded in showing that antisense treatment resulted in rapid interference with various cellular processes not primarily related to protein synthesis (8, 21) . In more detail, an antisense ODN complementary to the mRNA coding for oxytocin was infused bilaterally into the supraoptic nucleus of female rats. As early as 4 h later, marked changes were observed in sucklingrelated parameters including reduced number of milk ejection reflexes and reduced weight gain of the litter. These effects were accompanied by a less pronounced increase in circulating oxytocin, i.e. the sucklinginduced release of the peptide into the blood was significantly lower in antisense-treated rats. At first glance, these effects seemed to be due to a reduced availability of oxytocin in the hypothalamo-neurohypophysial system. However, this proved to be incorrect. Neither radioimmunological nor immunocytochemical detection of the immunoreactive peptide at hypothalamic and neurohypophysial levels revealed any changes in availability after antisense treatment. These findings clearly suggest a mechanism of action different from the 'classical' antisense mechanism. A similarly quick effect has recently been demonstrated by Meeker et al. (17) , who determined a drinking response as early as 4 h after bilateral injection of a vasopressin antisense ODN into the supraoptic nucleus. In this particular case, however, a 32-mer antisense ODN was compared with a sense control only. Hulsey et al. (22) demonstrated that repeated intracerebroventricular administration of an antisense ODN complementary to rat neuropeptide Y mRNA lowered food intake and body weight change. Interestingly, even prolonged antisense treatment did not cause a depletion of neuropeptide Y in the paraventricular nucleus, an area thought to be critically involved in feeding behavior, further supporting the possibility that behavioral alterations are not necessarily related to a depletion of the gene product. However, because of striking differences in local content, de novo synthesis, processing and release patterns, more neuropeptides have to be studied before final conclusions can be drawn.
We hypothesized that antisense ODN could either influence the characteristics of neuronal membranes or in some way interfere with the genetic machinery of neurons, thus rapidly affecting neuronal properties including secretion from distant terminals. The close coupling between electrical and secretory activity in the hypothalamo-neurohypophysial system is well known (23) . In order to investigate these possibilities, we examined acute effects of both oxytocin and vasopressin antisense ODN on electrophysiological parameters using an extracellular recording technique (24) . Indeed, the responsiveness of antidromically identified supraoptic neurons to relevant afferent stimuli (oxytocin neurons: intravenous cholecystokinin-8; vasopressin neurons: intravenous nitroprusside to reduce blood pressure) was selectively reduced in antisense-treated animals compared with vehicle, scramble-sequence and the corresponding other antisense ODN. In contrast, the basal firing rate of oxytocin and vasopressin neurons in the supraoptic nucleus did not differ among groups regardless of whether antisense ODN or scrambled-sequence ODN were given. This indicates an unchanged vitality of the extracellularly recorded neurons.
These findings suggest specific, short-term antisense effects not primarily related to an antisense mechanism of action such as translational arrest and depletion of the gene product. The reduced neuronal activity associated with the interference with gene expression per se rather than with gene product depletion demonstrates an interesting property of hypothalamic neurons, namely that their activity is blunted not as a consequence but in anticipation of reduced neuropeptide availability. Furthermore, these findings confirm the need to detect more than just a neuroendocrine or behavioral effect, i.e. to look for molecular and cellular correlates of an antisense-induced alteration. The more insight we gain into the variety of antisense mechanisms of action, the better use we will be able to make of this technology. In any case, one has to be aware that non-antisense mechanisms of action may be as specific and interesting as antisense mechanisms. This is true also for non-sequence-specific effects of antisense ODN, which may be as therapeutically useful as those labeled sequence-specific (7) .
Which of these mechanisms predominate in a particular brain area and under particular experimental conditions is generally unknown. Nevertheless, they may well be very critical for the eventual success or failure of antisense technology. Moreover, the specificity of antisense effects depends on a variety of parameters. One of these is the length of the antisense ODN, which is usually between 15 and 25 bases. Taking into account the total number of base pairs in the mammalian genome and the fraction of the genome transcribed, Héléne and Toulmé (25) have calculated that, statistically, antisense ODN of between 11 and 15 bases should be adequate to define a simple species of mRNA, i.e. should provide a sufficient margin of safety in this respect. The problem is that, by increasing the length of the antisense ODN to specify a unique mRNA, the hybridization potential of the ODN is also increased up to a point where stringency of hybridization can no longer be achieved under physiological conditions. Increased length also decreases penetration into the cells. Another issue is the targeted sequence on the mRNA. Most investigators begin with sequences around the initiation codon AUG or at RNA processing sites. The optimal sequence can be found only empirically. So far no in vivo study has been conducted to examine systematically the efficacy of targeting different domains of the same mRNA or the possibility of additive effects of several ODN contained in an antisense cocktail and complementary to different domains of a particular mRNA.
Effects of antisense ODN on neuroendocrine systems and behavior
Whenever possible, the targeted gene product should be measured in a functional context. Better than measurement of intracellular neuropeptide content, for example, is the detection of the biologically active neuropeptide after its release into different compartments and assessment of the physiological consequences. In this way, an antisense-induced deficit in vasopressin secretion may become evident as increased water consumption in rats (26), a deficit in oxytocin secretion as reduced milk ejection (21) and a deficit in corticotropinreleasing hormone (CRH), vasopressin and oxytocin as diminished secretion of adrenocorticotropin (ACTH) from the adenohypophysis (Fig. 1) . These paradigms are advantageous as the respective peptides are causally and critically involved in the physiological and endocrine consequences mentioned earlier. Generally less unequivocal is the involvement of endogenous substances in the regulation of behavior. With its emotional and cognitive components, behavioral performance is determined by multiple pathways and there is certainly hardly an intracerebral ligand or receptor that is not directly or indirectly involved in its control. Despite this rather blurred relationship between an induced deficit and behavioral performance (which, incidentally, may be even more blurred in knockout strategies), there are several arguments supporting the measurement of behavioral parameters after antisense treatment. First of all, central interventions such as antisense targeting are often of interest only if they are robust enough to influence behavior, i.e. the 'end point' of all regulative patterns. In other words, a clear-cut behavioral effect is believed to elevate more or less 'hidden' neurochemical alterations to functional significance. Furthermore, many behavioral tests can easily be done without additionally stressing the animal. Again, the problems necessarily associated with the blurred relationship between an antisense-induced deficit on the one hand and behavioral performance on the other can best be handled if the former is as specific as possible, transient, restricted to a certain brain area and sufficiently validated by proper chemical and biological controls.
Even though neuroendocrine and behavioral effects of antisense ODN are not measured together very often, they are generally closely interrelated. Examples of antisense effects on both neuroendocrine and behavioral parameters are given in Table 1 . Although not properly controlled in each case, these studies contribute substantially to our understanding of the causal involvement of single neuropeptides and neuropeptide or steroid receptors in behavioral regulation. A wide variety of neuropeptides, for example, could be shown to be related to drinking (vasopressin) and feeding (neuropeptide Y) behavior, reproductive behavior (oxytocin), grooming (b-endorphin) and anxietyrelated behavior (CRH) ( Table 1) . Focussing on receptor downregulation in specific brain areas, various behaviors could be altered, including anxiety-related behavior (vasopressin V1 and neuropeptide Y-Y1 receptors), lordosis (oxytocin and progesterone receptors), analgesia-related behaviors (opioid receptors), learning and memory (vasopressin V1 receptor), immobility (glucocorticoid receptors) and drinking responses (angiotensin II-1 receptor) ( Table 1) .
Other neuroendocrine studies did not explicitly focus on behavioral consequences of antisense treatment. Scarbrough et al. (27) and Harney et al. (28), for example, infused an antisense ODN to vasoactive intestinal peptide mRNA into the suprachiasmatic nucleus of rats and found a suppression of peptide levels in this nucleus, an attenuated luteinizing hormone surge and a temporary abolition of the corticosterone rhythm, but no effect on the stressrelated rise in this steroid. This approach took advantage of the fact that the treatment influenced neuropeptide terminals of suprachiasmatic neurons no matter how widely dispersed in the brain, because all vasoactive intestinal peptide is synthesized in this nucleus; the synaptic connections of this system have not yet been worked out. It would be of interest to detect behavioral consequences of a phase shift in the circadian rhythm. Prodynorphin antisense (and sense) treatment resulted in decreased peptide levels in the rat striatum (18) . Targeting the growth hormone receptor mRNA, Pellegrini et al. (20) detected a dose-dependent stimulation of growth hormone secretion and decreased somatogenic binding sites in the choroid plexus after intracerebroventricular administration.
In general, antisense targeting should be a particularly attractive tool for studying complex neuroendocrine pathways and circuits controlled by a variety of mediators at multiple brain levels. The hypothalamicpituitary-adrenal (HPA) axis fulfills this requirement. The paraventricular nucleus (PVN) of the hypothalamus contains many of the neurons that project to the median eminence, particularly those expressing CRH, vasopressin and oxytocin, neuropeptides with major roles in controlling ACTH secretion from the adenohypophysis (29). A fundamental role of the PVN in HPA axis regulation is implied by the finding that both CRH and vasopressin mRNAs are increased in this brain area after exposure to a variety of stressors (30). Although an influence exerted by ACTH secretagogues of extra-PVN origin cannot be entirely excluded (31), CRH and vasopressin released from PVN neurons are obligatory for adequate ACTH responses to stressful stimuli. In a first attempt at studying the contribution of PVN
R Landgraf and others

EUROPEAN JOURNAL OF ENDOCRINOLOGY (1997) 137
Figure 1 Effects on plasma ACTH levels of a cocktail containing antisense ODN (AS) to CRH, vasopressin and oxytocin mRNAs (800 ng each). Control rats received either corresponding scrambled sequences (SS) or vehicle (V) or remained untreated (C). The solutions were infused bilaterally into the PVN of male rats three times at 12-h intervals (arrows). Blood samples from the jugular vein were taken before (0800 h, samples 1 and 7; 1400 h, samples 3 and 9; 2000 h, samples 5 and 11) and after 5 min of forced swimming (FS). *P< 0.05 compared with V and C. neuropeptides to HPA axis regulation under basal and stressful conditions, we used antisense ODN to CRH, vasopressin and oxytocin mRNAs. An antisense cocktail containing the endcapped phosphorothioated ODN was infused bilaterally into the PVN of male rats three times at 12-h intervals. During daytime, the animals were repeatedly exposed to 5 min of forced swimming (Fig. 1) . The basic idea underlying this experimental design is that an antisense-induced deficit might not become evident under basal conditions but might be seen after repeated stress known to challenge the HPA axis, i.e. to stimulate ACTH secretagogue release from PVN neurons. Indeed, plasma ACTH was virtually identical under basal conditions in vehicle-, scrambled-sequenceand antisense-treated rats, but it was reduced in antisense-treated animals after forced swimming, a combined emotional and physical stressor, especially in the time intervals immediately following administration of the cocktail (Fig. 1) . We hope the experimental design can be further optimized so that the contribution of individual ACTH secretagogues and their intrahypothalamic interactions with the respective receptor subtypes can be determined. The latter are likely to be of particular impact, as has recently been shown for both CRH (32) and vasopressin (29, 33). Examples of antisense-induced behavioral (including autonomic) effects due to or associated with neuroendocrine alterations are given in Table 1 . Many of the antisense studies did not deal explicitly with neuroendocrine correlates of behavioral effects, but this by no means indicates that neuroendocrine alterations are not involved. In a variety of approaches modulatory antinociceptive effects have been reported in mice and rats after administration of antisense ODN to opioid receptors (34-47), the cholecystokinin-8 receptor (48), the alpha subunit of the G-protein (49) (50) (51) , the alpha-adrenergic receptor (47) and c-fos (52) .
Locomotor (rotational) behavior was found to be modulated by unilateral injection into the striatum or other specific brain areas with an antisense ODN to N-methyl-d-aspartate glutamate receptors (53) or dopamine receptors (54, 55) . Similarly, treatment with antisense ODN to immediate-early genes resulted in ipsilateral rotation (14, 56, 57) . Bilateral hippocampal administration of an antisense ODN complementary to glucocorticoid receptor mRNA reduced immobility during forced swimming due to a diminished receptor expression in the ipsilateral dentate gyrus (58) . Hyperactivity in mice was observed after delta-opioid receptor antisense (59) , and an antisense-induced loss of ACTH and b-endorphin immunoreactivity in the arcuate nucleus was associated with a substantial reduction in grooming behavior (60) .
Effects on feeding and drinking following various antisense ODN have been reported. Antisense directed towards the G-protein alpha unit, for example, decreased food intake without affecting water intake (61), whereas those directed towards CRF had a short-term stimulatory effect on feeding behavior (62) . As expected, vasopressin antisense treatment increased water intake (17, 26) and angiotensin II-1 receptor antisense attenuated the drinking response to angiotensin II (63, 64 ). An involvement of oxytocin and its receptor (65, 66) , of neuropeptide Y-Y1 receptors (67) and of the m receptor (68) in food intake has been suggested.
Numerous attempts have been made to downregulate receptor proteins involved in reproductive behaviors (69) (70) (71) . Intrahypothalamic administration of antisense ODN to progesterone receptor mRNA reduced mating behavior by 70-80%. The overall magnitude of inhibitory action on progesterone receptor immunoreactivity was smaller, indicating that behaviorally important actions of progesterone may be restricted to a small population of hypothalamic neurons (71) . Similarly, a reduction in female sexual receptivity (60%) and in oxytocin receptor density (31%) was detected after intrahypothalamic administration of antisense ODN to oxytocin receptor mRNA (65) . McCarthy et al. (72) provided evidence that antisense ODN can be used to alter behavior permanently by blocking specific gene expressions at certain developmental stages. Neonatal treatment with antisense ODN to estrogen receptor mRNA altered the androgenizing effect of testosterone in female rats. Antisense ODN to D5 but not to D1 dopamine receptor mRNA suppressed reproductive behavior associated with cocaine (73).
Liebsch et al. (74) used chronic infusion of a CRH1 receptor antisense ODN via osmotic minipumps directly into the area of the central nucleus of the amygdala and succeeded in measuring reduced anxiety-related behavior in socially defeated rats. In contrast, short-term memory remained unchanged in the same animals. Owing to the reportedly low expression and density of CRH1 receptors in the central nucleus, we failed to detect neuroendocrine correlates of this altered emotionality. Similarly, Pellegrini et al. (20) were unable to detect reproducible growth hormone binding in the hypothalamus of rats and, consequently, a further antisense-induced decrease, although other effects of receptor antisense treatment made this decrease likely. Reduced anxiety-related behavior was also observed after intraseptal administration of vasopressin V1 receptor antisense ODN to rats. The decrease in V1 receptor density in the septum was accompanied not only by a decreased emotionality but also by a deficit in short-term memory (12) . The former has subsequently been confirmed by injection of a selective V1 antagonist into the septal area (75) . Furthermore, anxiolytic effects have been observed after intracerebroventricular administration of CRH antisense ODN (76) or c-fos antisense infusion into the amygdala (77); signs of anxiety have been reported after intracerebroventricular neuropeptide Y antisense treatment (78) .
Learning and memory have been demonstrated to be affected by a variety of antisense ODN, including those to insulin-like growth factor (79), c-fos (80, 81) , c-jun (82) and the vasopressin V1 receptor subtype (12) .
Finally, antisense effects on cardiovascular (83) (84) (85) and temperature (67, 86, 87) regulation have been reported.
Conclusions
Antisense targeting substantially completes our repertoire of methodological tools rather than being an exceptional technique per se. Thus, exclusive reliance on antisense results to reveal the physiological significance of certain gene products may be misleading. In a first approach, antisense targeting should be 'standardized' on a brain system in which effects can be expected on the basis of known neuroendocrine and/or behavioral effects of conventional interventions (antagonists, neurotoxic agents, lesions, etc.). Nevertheless, when working with a novel or unexplored brain system, antisense targeting itself may pose several methodological problems that can affect the validity and selectivity of the approach.
The methodological criteria discussed for optimizing antisense efficacy while maintaining maximum selectivity may have to be determined empirically in each particular study. This may be a time-consuming and expensive procedure. Nonetheless, as shown in this review, a growing body of literature demonstrates antisense (and non-antisense) effects within the brain to be highly specific, locally restricted and reversible. In concert with other tools, antisense targeting will thus further contribute to revealing the physiological involvement of neuropeptides and receptor proteins in neuroendocrine and behavioral regulation. 
